| DNA Analysis | RNA Analysis |
|---|---|
|
|
The ACE Extended Cancer Panel covers a core set of over 1,400 cancer-related genes including clinically actionable* genes and genes that have been identified in the literature. It provides robust coverage of gene pathways and functions known to be involved in cancer biology and can be used to identify SNVs, indels, and copy number alterations. The accuracy of the ACE Extended Cancer Panel has been enhanced by augmenting and repairing coverage gaps, especially in regions with high-GC content. This approach results in the characterization of genes with more complete coverage.
*Genes referred to here as being clinically actionable reflects the fact that the efficacy of cancer drugs, FDA approved or in clinical trials, are thought to be modulated by variants in these genes. This does not imply that this panel is for clinical use – it is a Research Use Only service.
| Technical Details | |
|---|---|
| Genes covered | >1,400 |
| Depth of sequencing | >500x |
| Assay sensitivity | >99% |
| Assay specificity (PPA) | >99% |
| Sample source | FFPE, fresh frozen, fine needle aspirates, PBMCs |
| Analysis configuration | Tumor only or paired tumor and normal |
- Brochure: Oncology Research Services
The ACE Extended Cancer Panel for RNA provides unparalleled detection of unique variant types that are not identifiable by DNA sequencing analysis alone. The assay identifies gene expression levels, gene fusions, SNVs and indels in over 1,400 cancer-associated genes. This panel enables extensive gene fusion discovery of both clinically actionable* fusions involving critical genes such as ALK, ROS1, RET, and novel fusions involving other targeted genes that might be missed with DNA analysis alone.
Personalis’ targeted approach to RNA sequencing provides researchers with higher quality RNA results compared to those achieved by conventional transcriptome sequencing practices. We accomplish this by focusing only on genes related to cancer biology (by excluding intronic RNA from unspliced transcripts) and by using a capture method that can isolate degraded RNA better than other methods. This results in higher quality RNA reads with minimized background.
| Technical Details | |
|---|---|
| Genes covered | >1,400 |
| Sequencing configuration | Paired-end 2x 125 bp |
| Sample source | FFPE, fresh frozen, fine needle aspirates, PBMCs |
| Analysis configuration | Tumor only |
- Brochure: Oncology Research Services
Using our patented ACE Technology, the ACE Cancer Research Exome outperforms conventional exome assays by augmenting coverage across intronic and difficult-to-sequence (high-GC content) regions, ensuring the capture of variants that would be otherwise missed.
- Even coverage across all exons (>20,000 genes) and enhanced coverage of >8,000 biomedically-important genes, including >1,400 cancer-related genes.
- Augmentation and repair of coverage gaps, especially in high-GC regions.
- Somatic variant detection of SNPs, indels, and CNVs.
- Sample sparing protocols for all cancer sample types, including challenging sample types such as FFPE, fresh frozen, FNAs, and PBMCs.
| Technical Details | |
|---|---|
| Genes covered | >20,000 |
| Genes augmented | >8,000 biomedically important genes, including >1,400 cancer-related genes |
| Sequencing depth | ≥100x (tumor)/≥65x (normal) |
| Sample source | FFPE, fresh frozen, fine needle aspirates, PBMCs |
| Analysis configuration | Tumor only or paired tumor and normal |
- Brochure: Oncology Research Services
The same accuracy and coverage enhancements demonstrated by the ACE Cancer Research Exome (see above) are also incorporated into RNA analysis using our ACE Cancer Research Transcriptome enrichment protocol.
Many clinical studies depend on tissue archives that have been fixed using FFPE procedures. This preservation process makes it difficult to obtain a pure sample and often leads to RNA degradation. To overcome this challenge, Personalis has developed an exome-capture transcriptome protocol based on our ACE Technology that allows us to produce high-quality transcriptome sequencing results from challenging FFPE samples.
- Multiple probes target each transcript, capturing transcripts even when the poly-A tail is lost due to RNA degradation, making it ideal for cancer FFPE samples.
- Sequencing protocol demonstrates that >95% of the bases are mapped within the coding and UTR regions of the RNA.
- Fusion detection and gene expression analysis.
- Sample sparing protocols for all cancer sample types, including challenging sample types such as FFPE, fresh frozen, FNAs, and PBMCs.
| Technical Details | |
|---|---|
| Genes covered | >20,000 |
| Genes augmented | >8,000 biomedically important genes, including >1,400 cancer-related genes |
| Sequencing configuration | Paired-end 2×125 bp |
| Sample source | FFPE, fresh frozen, fine needle aspirates, PBMC |
| Analysis configuration | Tumor only |
- Brochure: Oncology Research Services
| DNA Analysis | RNA Analysis |
|---|---|
|
|
